The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
about
Validation of functional imaging as a biomarker for radiation treatment responseImaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilitiesCharacterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancerImaging biomarker roadmap for cancer studiesMagnetic resonance image guided brachytherapy.Quantification of proton dose calculation accuracy in the lung.Specific recommendations for accurate and direct use of PET-CT in PET guided radiotherapy for head and neck sites.(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patientsExploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot sMultiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.Short-course PET based simultaneous integrated boost for locally advanced cervical cancerPharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer.In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.Functional imaging for radiotherapy treatment planning: current status and future directions-a review.Personalized radiotherapy treatment planning based on functional imaging.Hypoxia imaging and radiotherapy: bridging the resolution gap.Correlation analysis of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy.Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy.PET in the management of locally advanced and metastatic NSCLC.Image-guided radiotherapy and motion management in lung cancer.Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.A novel 3D-printed phantom insert for 4D PET/CT imaging and simultaneous integrated boost radiotherapy.Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging.FDG and Beyond.Predictive treatment management: incorporating a predictive tumor response model into robust prospective treatment planning for non-small cell lung cancer.The mean lung dose (MLD) : predictive criterion for lung damage?Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomographyImpact of CT attenuation correction method on quantitative respiratory-correlated (4D) PET/CT imaging.Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer.Magnetic resonance imaging in precision radiation therapy for lung cancer.Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT.
P2860
Q26823165-D3C5234A-C655-4A89-BF6A-26CD9DFD2432Q27025204-6A055296-15D8-4ACA-ADDB-DDFA2A1DCB7AQ27304358-8228AE42-8B17-4825-81D5-329F29FAD43FQ30242020-4843AC0B-3962-4672-ACEE-A39ACCF6ADAAQ30586499-BA8079DB-2E86-43A4-BDC4-E53985736E73Q33638795-210DB5D6-3BFF-46D0-AA61-87689ACCF222Q35138065-2FAF2E7C-2E54-4468-8477-C64386F4FD89Q35870847-5AC63B4C-08AC-4BCC-975D-98579B875D2AQ36104455-633EA009-C0A5-4A64-B83C-E0D416ACAABCQ36153707-B25C0320-BD59-47D6-AEA6-BFFF3728CB14Q36427037-B1813C88-CD58-4C9C-838A-8FC302D1D452Q36679179-DE72A185-17BA-481D-A8A9-5469DBA1ED0EQ37496776-E88E97A9-800B-424B-81FD-7A0E9BC6E334Q37581964-E650C70B-02C6-4A49-A188-3232AC027151Q38397651-FD5895A5-ED7F-45B0-A7FC-E85F770E50C8Q38400305-27F6685D-7705-4639-8C9D-A1306C1A0141Q38400842-A82D89C6-9922-4637-9475-BFC5CA32A9F3Q38400856-BFE90353-63FE-4B07-BFC3-7C10CF2FB641Q38401313-E1A53395-F6D3-40D1-AE33-D00B66BC7445Q38401906-93F87FEC-58E0-4EFE-A74A-0CF52FE18E92Q38424780-6B09A021-E157-4C3D-9816-BCEAB18DF78CQ38444980-D5C85FED-B38B-49B4-BF8C-3BA07518B44EQ38467341-D616C42D-53F2-42B6-956B-98BAA58F206DQ38608607-21EF224C-7F62-407F-B424-8643FC35BF47Q38647290-31C9D088-0E10-485A-BE4E-32BA3C4F7613Q38725176-0E60525E-9D48-46FD-9005-00AD48537CC5Q38869438-E733A568-E75F-4FC8-9BDE-25D7B389FE52Q38903628-2295B2BA-EAD1-4026-892F-B3C475FE8315Q41085965-1D23217E-3520-4213-B2FF-24746B0E7F5AQ41550760-906DFC8A-06F0-41AB-A5AC-71BC2D76DE6AQ41625221-E3F97BAB-CEEE-40C2-AFAA-7F1750D0D2C8Q42355410-D37AF366-4880-49AB-98B6-2841E7F399F8Q42907283-50CE0EF1-2C3A-4063-B35E-D251C7669CE0Q44174829-8400933D-24B2-43DC-A9DA-054B63CF3514Q47108915-4C4F4F92-20A8-4639-8D93-CD71B6543380Q47138202-1F26448B-892B-4EB2-8E75-AD3FC2ACB0D9Q47591667-A76EE8FE-0950-4FBF-8651-D24E8193400BQ47769995-D70ED370-96FA-4C75-A5BC-96EB384C4260Q47777467-E7408528-F569-4F12-91FA-609870CD57D3Q48181398-DF8DED86-921F-4C23-B2F3-40DB90D21AE3
P2860
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@en
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@nl
type
label
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@en
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@nl
prefLabel
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@en
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@nl
P2093
P1476
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
@en
P2093
Anke van der Salm
Annemarie Lakeman
Daisy Emans
Eugène Damen
Jan-Jakob Sonke
José Belderbos
Judith van der Stoep
Michel Öllers
P356
10.1016/J.RADONC.2012.03.005
P577
2012-04-06T00:00:00Z